<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="100021"><DrugName>tranexamic acid (topical, melasma), Hyundai</DrugName><DrugNamesKey><Name id="156621">tranexamic acid</Name></DrugNamesKey><DrugSynonyms><Name><Value>tranexamic acid</Value><Types><Type>INN</Type></Types></Name><Name><Value>tranexamic acid (topical, melasma), Hyundai</Value></Name><Name><Value>HTB-003</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HDDT-1603</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1197-18-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="2011" type="ciIndication"><TargetEntity id="L81.1" type="ICD10"></TargetEntity><TargetEntity id="H02.71" type="ICD10"></TargetEntity><TargetEntity id="10008570" type="MEDDRA"></TargetEntity><TargetEntity id="3491" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1571" type="Action"><TargetEntity id="1137" type="Mechanism">Plasmin Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01583" type="ciTarget"><TargetEntity id="17366577953403" type="siTarget">Plasminogen</TargetEntity><TargetEntity id="-853568211" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="2011">Melasma</Indication></IndicationsSecondary><ActionsPrimary><Action id="1571">Plasmin inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="611">Dermatological formulation</Technology></Technologies><LastModificationDate>2018-01-23T16:11:28.000Z</LastModificationDate><ChangeDateLast>2017-07-24T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was developing HDDT-1603 (previously HTB-003), a topical formulation of the plasmin inhibitor tranexamic acid, incorporating the company's Transdermal Accelerating Technology, for the potential treatment of melasma [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;], [&lt;ulink linkID="1723864" linkType="Reference"&gt;1723864&lt;/ulink&gt;]. In November 2015, the drug was in phase II development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. However, the program was no longer listed on Hyundai's July 2017 pipeline [&lt;ulink linkID="1946873" linkType="Reference"&gt;1946873&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2011">Melasma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2011">Melasma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-09-28T00:00:00.000Z</StatusDate><Source id="1723864" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2011">Melasma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01583"><Name>Plasmin</Name><SwissprotNumbers><Swissprot>P00747</Swissprot><Swissprot>P06867</Swissprot><Swissprot>P06868</Swissprot><Swissprot>P20918</Swissprot><Swissprot>P80009</Swissprot><Swissprot>P80010</Swissprot><Swissprot>Q01177</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C1[C@@H](CC[C@H](C1)C(=O)O)CN</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2811796" number="WO-2014163338" title="Composition for external use preparation with improved transdermal permeability"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hyundai Pharmaceutical" id="22606"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>